Breaking News, Collaborations & Alliances

Asimov, Ottimo Pharma Enter Cell Line Development Partnership

This partnership will accelerate Ottoimo Pharma’s cancer immunotherapy’s path to clinic.

By: Rachel Klemovitch

Assistant Editor

Asimov, a synthetic biology company, entered a cell line development partnership with Ottimo Pharma, a biopharmaceutical company developing PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer.  The collaboration centered on cell line development for Ottimo’s lead program, OTP-01, a PD1/VEGFR2 dual pathway antibody. Asimov has delivered a high-titer, stable CHO cell line ahead of schedule to support an IND submission planned for late 2025. Asimov began ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters